Patents Represented by Attorney Peter C. Richardson
  • Patent number: 7301023
    Abstract: A method for resolving enantiomers of a compound containing the structure of the forula: wherein R4 or R5 may contan one or more asymmetric centers, by mixing a racemic mixture of enantiomers of a compound, containing the structure of said formula; in a solvent, with a resolving compound having a defined sterospecificity, to form a solution and with said resolving agent being capable of binding with at least one but not all of said enantiomers to form a precipitate, containing said at least one of said enantiomers in sterospecific form and collecting either the precipitate and purifying it or collecting the solution with contained other of said enantiomers and recrystallizing the enantiomer contained in said solution.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: November 27, 2007
    Assignee: Pfizer Inc.
    Inventors: Mark E. Flanagan, Michael J. Munchhof
  • Patent number: 7122565
    Abstract: The invention provides 1,3,4-thiadiazoles and 1,3,4-oxadiazoles having the following Formula I: in which, Y is S or O, R1 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl or a polycyclic group, optionally substituted, R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl or aryl optionally substituted, R3 is X2—R?3, in which X2 is a binding group and R?3 is cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl, or a polycyclic group; optionally substituted, or their pharmaceutically acceptable derivatives, a compound of Formula I, for their preparation, and processes for pharmaceutical compositions containing methods of using the compounds for the treatment of disorders for which a treatment by a PDE7 inhibitor is relevant.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: October 17, 2006
    Assignee: Warner-Lambert LLC
    Inventors: Fabrice Vergne, Pierre Ducrot, Charles Andrianjara, Patrick Bernardelli, Edwige Lorth Ois
  • Patent number: 7122534
    Abstract: The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: October 17, 2006
    Assignee: Pfizer Inc
    Inventor: Jotham Wadsworth Coe
  • Patent number: 7101869
    Abstract: Novel compounds according to the formula and pharmaceutically acceptable salts, solvates, or hydrates thereof; wherein each occurrence of A is independently selected from CH or N; X is selected from the group consisting of —CH2—, —O—, —NH—, (C1-C6)alkylamino-, (C1-C6)alkylaminocarbonylamino-, (C1-C6)alkylcarbonylamino-, (C1-C6)alkylsulfonylamino-, phenylsulfonylamino-, carbonyl, —NH—C(O)—, —N(C1-C6)alkyl-C(O)—, —S(O)y— where y is 0, 1 or 2, and; n in —(CH2)n— is 1, 2 or 3; and R1, R2, and R3 are as described herein; pharmaceutical compositions that including these compounds, and methods for the treatment of autoimmune disease, inflammation, allergy, transplant rejection, and other circumstances where administration of an immunosuppressive agent is of therapeutic benefit.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: September 5, 2006
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Eileen Elliott Mueller, Eric Jan Roskamp
  • Patent number: 7084165
    Abstract: The present invention relates to compounds that are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: September 4, 2003
    Date of Patent: August 1, 2006
    Assignee: Pfizer Inc
    Inventors: Harry Ralph Howard, Jr., Christopher Joseph Schmidt, Thomas Francis Seeger, Mark Leonard Elliot
  • Patent number: 7067493
    Abstract: The present invention relates to a method of treating infections in humans by administering a single dose of azithromycin.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: June 27, 2006
    Assignee: Pfizer Inc.
    Inventor: Michael W. Dunne
  • Patent number: 7053192
    Abstract: The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: May 30, 2006
    Assignee: Pfizer Inc.
    Inventors: Zheng J. Li, Andrew V. Trask
  • Patent number: 7022684
    Abstract: The invention described herein relates to: the use of an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase in the manufacture of a composition for the treatment of rumen acidosis; a method of treatment of rumen acidosis which comprises administration of an effective amount of an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase to a ruminant; a formulation suitable for the treatment of rumen acidosis in an animal which comprises an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase in admixture with a suitable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical/veterinary/farming practice; screening methods useful in the identification of a suitable inhibitor of a bacterial ?-amylase and/or ?-glucosidase for the treatment of acidosis in a ruminant; a process for improving ruminant milk quality and/or quantity which comprises treatment of a ruminant with an effective amount of an inhibitor of bacte
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: April 4, 2006
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Mark Andrew Haxell, Graham Lunn, Michael Stephen Pacey, Lee Richard Roberts
  • Patent number: 7019033
    Abstract: Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, and Z is COOR7, tetrazolyl, CONR6R7, or CH2OR7, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: March 28, 2006
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
  • Patent number: 7019016
    Abstract: The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: March 28, 2006
    Assignee: Pfizer Inc
    Inventors: Bertrand L. Chenard, Frank S. Menniti, Mario D. Saltarelli
  • Patent number: 6992087
    Abstract: Substituted aryl 1,4-pyrazine derivatives of formula I as defined herein and their use in treating anxiety disorders, depression and stress related disorders are disclosed.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: January 31, 2006
    Assignee: Pfizer Inc
    Inventors: Patrick R. Verhoest, Robert Louis Hoffman, Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu
  • Patent number: 6979741
    Abstract: Acetyl Coenzyme A Carboxylase inhibitors, pharmaceutical compositions containing such compounds and the use of such compounds to treat for example, Metabolic Syndrome including atherosclerosis, diabetes and obesity.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: December 27, 2005
    Assignee: Pfizer Inc.
    Inventors: David A. Perry, H. James Harwood
  • Patent number: 6977302
    Abstract: The invention provides compounds of formula I, R1—OP(O)(OH)2??I wherein R1 represents the non-hydroxy portion of a triazole antifungal compound of the type comprising a tertiary hydroxy group; or a pharmaceutically acceptable sat thereof. The compounds of the invention are useful in the treatment of fungal infections, and have good aqueous solubility.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: December 20, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stuart Green, Peter T. Stephenson, Martha H. Murtiashaw, Charles W. Murtiashaw
  • Patent number: 6974803
    Abstract: The present invention relates to a combination comprising (a) an adenosine A2a receptor agonist as defined herein and (b) an adrenergic ?2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: December 13, 2005
    Assignee: Pfizer Inc
    Inventor: Michael Yeadon
  • Patent number: 6974828
    Abstract: Novel propanoic acid derivatives are integrin receptor antagonists or inhibitors, in particular of the avb3 integrin receptor. The compounds of the invention are for instance useful for the treatment of solid tumors by inhibition of angiogenic growth of tumor vessel network, thus promoting tumor regression, inhibition of metastatic spread, thus avoiding cancer metastases, inhibition of bone resorption, thus controlling osteoporosis, inhibition of smooth muscle cells migration into neointima, thus blocking restenosis after percutaneous coronary angioplasty and the treatment of other pathological conditions mediated by cell adhesion, cell migration or angiogenesis such e.g. diabetic retinopaty, rheumatoid arthritis and inflammation.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: December 13, 2005
    Assignee: Pharmacia Italia S.p.A.
    Inventors: Tiziano Bandiera, Paola Vianello, Paolo Cozzi, Arturo Galvani
  • Patent number: 6972287
    Abstract: The present invention provides a method of treating Alzheimer's disease using a compound of Formula (I). Also provided is a method of inhibiting the aggregation of amyloid proteins using a compound of the Formula (I) and a method of imaging amyloid deposits, as well as new compounds of Formula (I).
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: December 6, 2005
    Assignee: Pfizer Inc.
    Inventors: Corinne Elizabeth Augelli-Szafran, Mark Robert Barvian, Christopher Franklin Bigge, Shelly Ann Glase, Shunichiro Hachiya, John Steven Kiely, Takenori Kimura, Yingjie Lai, Annette Theresa Sakkab, Mark James Suto, Larry Craswell Walker, Tomoyuki Yasunaga, Nian Zhuang
  • Patent number: 6972298
    Abstract: The present invention provides a method of treating or preventing neutrophil chemotaxis. Specifically, the present invention provides a method of treating or preventing neutrophil migration by administering to a patient a MEK inhibitor.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: December 6, 2005
    Assignee: Warner-Lambert Company
    Inventors: Vijaykumar M. Baragi, Madhav Narasimha Devalaraja, Joseph Edwin Low, Vaishalee A. Padgaonkar
  • Patent number: 6967204
    Abstract: This invention is directed to a method of treating insulin resistance syndrome (IRS), hypertension and/or type 2 diabetes in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor or a pharmaceutical composition thereof. This invention is also directed to such methods wherein said cGMP PDE9 inhibitor is used in combination with other agents to treat IRS, hypertension and/or type 2 diabetes.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: November 22, 2005
    Assignee: Pfizer Inc
    Inventors: David A. Fryburg, Earl Michael Gibbs
  • Patent number: 6965027
    Abstract: This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: November 15, 2005
    Assignee: Pfizer Inc.
    Inventors: Mark E. Flanagan, Zheng J. Li
  • Patent number: 6964957
    Abstract: Pyrazole compounds represented by the formula: are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in treating ERAB, HADH2 or amyloid-? mediated diseases and conditions.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: November 15, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Melwyn A. Abreo, Jerry J. Meng, Charles S. Agree